Aligos Therapeutics (ALGS) to Post Earnings on Wednesday

Aligos Therapeutics (NASDAQ:ALGS) will likely be issuing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of ($1.41) per share and revenue of $24.6750 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 9:30 AM ET.

Aligos Therapeutics (NASDAQ:ALGS) last issued its earnings results on Thursday, May 7th. The company reported ($2.21) EPS for the quarter, beating the consensus estimate of ($2.29) by $0.08. Aligos Therapeutics had a negative net margin of 1,919.68% and a negative return on equity of 139.47%. The company had revenue of $2.83 million for the quarter, compared to the consensus estimate of $0.25 million. On average, analysts expect Aligos Therapeutics to post $-7 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Aligos Therapeutics Stock Performance

ALGS opened at $4.25 on Wednesday. The firm’s 50-day simple moving average is $5.48 and its 200-day simple moving average is $6.64. Aligos Therapeutics has a twelve month low of $3.98 and a twelve month high of $13.69. The firm has a market cap of $26.31 million, a price-to-earnings ratio of -0.49 and a beta of 2.26.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ALGS. Wall Street Zen raised shares of Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday, May 17th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aligos Therapeutics in a research note on Friday, May 29th. Lake Street Capital started coverage on shares of Aligos Therapeutics in a report on Thursday, May 28th. They set a “buy” rating and a $45.00 price objective for the company. Finally, Weiss Ratings upgraded shares of Aligos Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Aligos Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.50.

Institutional Trading of Aligos Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ALGS. Woodline Partners LP bought a new position in shares of Aligos Therapeutics in the first quarter valued at about $2,602,000. Marshall Wace LLP bought a new position in Aligos Therapeutics in the 4th quarter worth approximately $2,504,000. SummitTX Capital L.P. bought a new position in Aligos Therapeutics in the 4th quarter worth approximately $1,299,000. Verition Fund Management LLC acquired a new position in Aligos Therapeutics during the 4th quarter worth $664,000. Finally, Vanguard Group Inc. lifted its holdings in Aligos Therapeutics by 22.8% during the 3rd quarter. Vanguard Group Inc. now owns 171,689 shares of the company’s stock worth $1,683,000 after buying an additional 31,913 shares in the last quarter. 60.43% of the stock is currently owned by institutional investors and hedge funds.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.